A5043846829- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Diet, Metabolism, and Disease
- Liver Diseases and Immunity
- Alcohol Consumption and Health Effects
- Hepatitis C virus research
- Radiomics and Machine Learning in Medical Imaging
- Diet and metabolism studies
- Pancreatitis Pathology and Treatment
- Hepatitis B Virus Studies
- Endoplasmic Reticulum Stress and Disease
- Lipid metabolism and disorders
- Cardiovascular Disease and Adiposity
- Organ Transplantation Techniques and Outcomes
- Folate and B Vitamins Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gut microbiota and health
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Cardiovascular Function and Risk Factors
- Diabetes Treatment and Management
- Liver physiology and pathology
- MRI in cancer diagnosis
- Metabolism and Genetic Disorders
Cedars-Sinai Medical Center
2016-2025
Methodist Hospital
2022-2025
Houston Methodist
2022-2025
Houston Institute for Clinical Research
2022-2024
National University of Singapore
2024
National University Health System
2024
Sorbonne Université
2024
Texas Liver Institute
2019-2024
Inserm
2024
Boehringer Ingelheim (Germany)
2024
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for the treatment of NASH fibrosis. Download PDF Research Summary. We are conducting ongoing phase 3 trial involving adults biopsy-confirmed and fibrosis stage F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned 1:1:1 ratio receive once-daily...
The magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) is a novel imaging-based biomarker that allows mapping of the entire liver, whereas spectroscopy-measured (MRS-PDFF) provides biochemical measure liver in small regions interest. Cross-sectional studies have shown MRI-PDFF correlates with MRS-PDFF. aim this study was to show utility assessing quantitative changes through three-way comparison and MRS-PDFF histology-determined steatosis grade at two time points...
Chronic infection with hepatitis C virus (HCV) was previously the leading indication for liver transplant (LT) in United States. However, since 2014 use of direct-acting antivirals (DAAs) has decreased chronic HCV burden, while prevalence nonalcoholic steatohepatitis (NASH) risen substantially through last decade. Both gender and ethnic disparities indications LT have been shown past but no data on this reported implementation DAAs.We assessed changes etiologies listing differences those...
Ezetimibe inhibits intestinal cholesterol absorption and lowers low-density lipoprotein cholesterol. Uncontrolled studies have suggested that it reduces liver fat as estimated by ultrasound in nonalcoholic steatohepatitis (NASH). Therefore, we aimed to examine the efficacy of ezetimibe versus placebo reducing magnetic resonance imaging-derived proton density-fat fraction (MRI-PDFF) histology patients with biopsy-proven NASH. In this randomized, double-blind, placebo-controlled trial, 50 NASH...
Chronic liver disease (CLD) and cirrhosis are major sources of morbidity mortality in the United States. Little is known about epidemiology these two diseases ethnic minority populations We examined prevalence CLD by underlying etiologies among African Americans, Native Hawaiians, Japanese Latinos, whites Multiethnic Cohort. cases were identified using Medicare claims between 1999 2012 fee‐for‐service participants (n = 106,458). used International Classification Diseases Ninth Revision...
We evaluated the safety and efficacy of cilofexor (formerly GS-9674), a small-molecule nonsteroidal agonist farnesoid X receptor, in patients with nonalcoholic steatohepatitis (NASH).In this double-blind, placebo-controlled, phase 2 trial, 140 noncirrhotic NASH, diagnosed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) ≥8% liver stiffness ≥2.5 kPa elastography (MRE) or historical biopsy, were randomized to receive 100 mg (n = 56), 30 placebo 28) orally once daily for 24...
Increased levels of galectin 3 have been associated with nonalcoholic steatohepatitis (NASH) and contribute to toxin-induced liver fibrosis in mice. GR-MD-02 (belapectin) is an inhibitor that reduces portal hypertension rats was safe well tolerated phase 1 studies. We performed a 2b, randomized trial the safety efficacy patients NASH, cirrhosis, hypertension.Patients (hepatic venous pressure gradient [HVPG] ≥ 6 mm Hg) from 36 centers were randomly assigned, double-blind manner, groups...
NAFLD is characterized by insulin resistance and dysregulated lipid glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves sensitivity, glycemic parameters. Saroglitazar improved NASH histology in animal studies. In this randomized controlled clinical trial, we evaluated the efficacy safety of saroglitazar patients with NAFLD/NASH.A total 106 NAFLD/NASH alanine aminotransferase (ALT) ≥ 50 U/L at baseline body mass index ≥25 kg/m2 were...
Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease.In this phase 2b trial, 392 patients with bridging or compensated cirrhosis (F3-F4) were randomized receive placebo, selonsertib 18 mg, cilofexor 30 firsocostat 20 alone in two-drug combinations, once-daily for 48 weeks. The primary endpoint was ≥1-stage improvement without worsening between baseline and weeks based on central pathologist review. Exploratory endpoints included changes NAFLD Activity Score...
Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity mortality. Given the complex pathophysiology NASH, combining therapies complementary mechanisms may be beneficial. This trial evaluated safety efficacy semaglutide, a glucagon-like peptide-1 receptor agonist, alone in combination farnesoid X agonist cilofexor and/or acetyl-coenzyme A carboxylase inhibitor firsocostat patients NASH.This was phase II, open-label,...
BackgroundDual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) may be more effective than GLP-1 alone for treating metabolic dysfunction–associated steatohepatitis (MASH). The efficacy safety survodutide (a dual agonist receptor) in persons with MASH liver fibrosis are unclear.MethodsIn this 48-week, phase 2 trial, we randomly assigned adults biopsy-confirmed stage F1 through F3 a 1:1:1:1 ratio to receive once-weekly subcutaneous injections at dose 2.4, 4.8, or 6.0 mg...